Intermediate-dose intravenous melphalan and blood stem cells mobilized with sequential GM+G-CSF or G-CSF alone to treat AL (amyloid light chain) amyloidosis.
about
Low doses of GM-CSF (molgramostim) and G-CSF (filgrastim) after cyclophosphamide (4 g/m2) enhance the peripheral blood progenitor cell harvest: results of two randomized studies including 120 patientsHigh-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial.Homing and mobilization of hematopoietic stem cells and hematopoietic cancer cells are mirror image processes, utilizing similar signaling pathways and occurring concurrently: circulating cancer cells constitute an ideal target for concurrent treatmAntibody-mediated resolution of light chain-associated amyloid deposits.Modified high-dose melphalan and autologous SCT for AL amyloidosis or high-risk myeloma: analysis of SWOG trial S0115.Current status of hematopoietic cell transplantation in the treatment of systemic amyloid light-chain amyloidosis.Light-chain amyloidosis: SCT, novel agents and beyond.High incidence of gastrointestinal tract bleeding after autologous stem cell transplant for primary systemic amyloidosis.Trends in day 100 and 2-year survival after auto-SCT for AL amyloidosis: outcomes before and after 2006.Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial.Autologous stem cell transplantation in primary systemic amyloidosis: the impact of selection criteria on outcome.Four patients with AL amyloidosis treated with high-dose chemotherapy and autologous stem cell transplantation.AL Amyloidosis, A Curable Disease?
P2860
Q24684280-662BBA77-D558-495B-BEC1-548A6E7BDF6EQ31032765-C2BBA610-1BFA-4C0B-912B-1BCF1231478FQ35566338-0F8DCC92-86C7-43BA-B08F-89DF68169D1DQ35745765-C59BAFE3-31D9-4FFA-B276-A492C448AC60Q37373292-24366146-698F-4AFB-A875-01D8AB313784Q37904673-9C1B0DAA-342D-40B6-81B7-638835E8F7D8Q38056010-36EB32DE-1408-4CED-8FA6-E1158403A1A1Q44210765-734268C5-B99A-4EF5-86A9-1CEDB48193AEQ44468671-18AE5991-F084-4BE5-99FA-2EC83DF868B9Q46980729-66804F41-7DE9-45B5-BC7F-0CEAE5E08B63Q52957346-EF450346-032B-4BB5-BD1E-212EC0AEE826Q52965372-69C70026-5A41-4C35-B587-399E5615647DQ58162286-8725B345-1B23-4ABE-A099-84395D67CBCB
P2860
Intermediate-dose intravenous melphalan and blood stem cells mobilized with sequential GM+G-CSF or G-CSF alone to treat AL (amyloid light chain) amyloidosis.
description
1999 nî lūn-bûn
@nan
1999 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի մարտին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Intermediate-dose intravenous ...... loid light chain) amyloidosis.
@ast
Intermediate-dose intravenous ...... loid light chain) amyloidosis.
@en
type
label
Intermediate-dose intravenous ...... loid light chain) amyloidosis.
@ast
Intermediate-dose intravenous ...... loid light chain) amyloidosis.
@en
prefLabel
Intermediate-dose intravenous ...... loid light chain) amyloidosis.
@ast
Intermediate-dose intravenous ...... loid light chain) amyloidosis.
@en
P2093
P2860
P1476
Intermediate-dose intravenous ...... loid light chain) amyloidosis.
@en
P2093
Comenzo RL
Sanchorawala V
P2860
P304
P356
10.1046/J.1365-2141.1999.01216.X
P407
P577
1999-03-01T00:00:00Z